Literature DB >> 18787398

The role of glypican-3 in the regulation of body size and cancer.

Jorge Filmus1, Mariana Capurro.   

Abstract

Glypicans are a family of heparan sulfate proteoglycans whose members are bound to the cell surface by a glycosylphosphatidylinositol (GPI) anchor. Loss-of-function mutations in GPC3, one of the six mammalian glypicans, causes the Simson-Golabi-Behmel Syndrome. This is a disorder characterized by pre- and post-natal overgrowth, a broad spectrum of visceral and skeletal abnormalities, and an increased risk for the development of embryonic tumors. GPC3-null mice also display significant overgrowth. We have recently reported that GPC3 acts as a negative regulator of Hedgehog signaling during development, and that the overgrowth caused by the lack of functional GPC3 is due, at least in part, to the hyperactivation of Hedgehog signaling. Here we discuss the rationale that led us to hypothesize that GPC3 could be a negative regulator of Hedgehog signaling, and speculate about the implications of our discovery regarding the role of GPC3 in some cancer types. We also discuss our recent results of experiments that investigated the role of the core protein, the heparan sulfate chains, and the GPI anchor in GPC3 function. Finally, we propose an explanation for the tissue-specific function of GPC3.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787398     DOI: 10.4161/cc.7.18.6672

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  31 in total

Review 1.  An introduction to proteoglycans and their localization.

Authors:  John R Couchman; Csilla A Pataki
Journal:  J Histochem Cytochem       Date:  2012-09-26       Impact factor: 2.479

Review 2.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.

Authors:  Min Yao; Li Wang; Zhizhen Dong; Qi Qian; Yun Shi; Dandan Yu; Shiye Wang; Wenjie Zheng; Dengfu Yao
Journal:  Tumour Biol       Date:  2014-03-16

4.  [Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma].

Authors:  Yuan-Yuan Wang; Chen-Jie Zhou; Jing Li; Ling Zhou; Ming-Song Li; Bing Xiao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-08-20

5.  The possible role of Sirtuins and microRNAs in hepatocellular carcinoma therapy.

Authors:  Hedyieh Karbasforooshan; A Wallace Hayes; Nooshin Mohammadzadeh; Mohammad Reza Zirak; Gholamreza Karimi
Journal:  Cell Cycle       Date:  2020-11-09       Impact factor: 4.534

6.  Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice.

Authors:  Bowen Liu; Aaron W Bell; Shirish Paranjpe; William C Bowen; Jaspal S Khillan; Jian-Hua Luo; Wendy M Mars; George K Michalopoulos
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 7.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 8.  Pattern, growth, and control.

Authors:  Arthur D Lander
Journal:  Cell       Date:  2011-03-18       Impact factor: 41.582

Review 9.  Glypicans as Cancer Therapeutic Targets.

Authors:  Nan Li; Wei Gao; Yi-Fan Zhang; Mitchell Ho
Journal:  Trends Cancer       Date:  2018-09-28

10.  Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation.

Authors:  Bowen Liu; Shirish Paranjpe; William C Bowen; Aaron W Bell; Jian-Hua Luo; Yan-Ping Yu; Wendy M Mars; George K Michalopoulos
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.